131069-91-5 Usage
Uses
Used in Diagnostic Imaging:
GADOVERSETAMIDE (200 MG) is used as a diagnostic aid for patients with anomalous blood-brain barrier or anomalous vascularity in the central nervous system or in the liver. It is particularly effective in imaging the brain, spine, and liver, as it enhances the visualization of lesions, including tumors.
Used in MRI Contrast Enhancement:
GADOVERSETAMIDE (200 MG) is used as a contrasting imaging agent in magnetic resonance imaging (MRI) procedures. It belongs to the class of extracellular contrast agents and is well-tolerated, making it a suitable choice for patients undergoing MRI scans.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, GADOVERSETAMIDE (200 MG) is used as a key component in the formulation of MRI contrast agents. Its paramagnetic properties and ability to enhance the visualization of lesions make it a valuable asset in the development of diagnostic tools for various medical applications.
Brand Name:
Optimark (Mallinckrodt) is the brand name under which GADOVERSETAMIDE (200 MG) is marketed and distributed.
Originator
Mallinckrodt (US)
Manufacturing Process
A stirred suspension of diethylenetriaminepentaacetic acid dianhydride (10.8
g, 0.030 mole) in 100 ml of isopropanol was treated with 2-
methoxyethylamine (5.0 g, 0.067 mole). The entire mixture was heated at
50°C for 4 hours in a water bath. The pale yellow solution was filtered
through a medium porosity sintered glass funnel to remove undissolved
impurities, and the filtrate was taken to dryness under reduced pressure. The
resulting amorphous foam was dried (vacuum desiccator) at ambient
temperature for 18 hours. The yield of the N,N"-bis[N-(2-methoxyethyl)-
carbamoylmethyl]diethylenetriamine-N,N',N"-triacetic acid 14.4 g (93.5%).
A mixture of gadolinium (III) oxide (3.3 g, 0.0091 mole) and N,N"-bis[N-(2-
methoxyethyl)-carbamoylmethyl]diethylenetriamine-N,N',N"-triacetic acid
(10.2 g, 0.020 mole) in H2O (100 ml) was heated at 60-65°C for 3 hours in a
water bath. The pale yellow homogeneous solution was filtered through a fine
porosity sintered glass funnel to remove undissolved impurities and the clear
filtrate was poured into acetone (2 L). The heterogeneous mixture was stirred
for 5 min and allowed to stand at ambient temperature for 30 min. Aqueous
acetone was decanted off and the resulting gummy residue was dissolved with
methanol (150 ml). The solution was concentrated under reduced pressure
and the complex was precipitated from the solution by adding it to more
acetone (1 L). The amorphous precipitate was collected, washed with acetone
and dried. The yield of {N,N"-bis[N-(2-methoxyethyl)-carbamoylmethyl]
diethylenetriamine-N,N',N"-triaceto}gadolinium (III) was 11.2 g (80.7%). The
pale cream solid was crystallized from a mixture of methanol and
tetrahydrofuran to give a colorless solid. It was 97.4% pure by HPLC. For {N,N"-bis[N-(2-methoxyethyl)-carbamoylmethyl]diethylenetriamine-N,N',N"-
triaceto}gadolinium (III) calculated: Gd, 22.88%, found: Gd, 22.52%.
Therapeutic Function
Diagnostic aid
Check Digit Verification of cas no
The CAS Registry Mumber 131069-91-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,0,6 and 9 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 131069-91:
(8*1)+(7*3)+(6*1)+(5*0)+(4*6)+(3*9)+(2*9)+(1*1)=105
105 % 10 = 5
So 131069-91-5 is a valid CAS Registry Number.
InChI:InChI=1/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);/q;+3/p-3
131069-91-5Relevant articles and documents
PREPARATION OF COMPLEXING AGENTS AND METAL ION COMPLEXES IN AQUEOUS MEDIA
-
Page/Page column 24, (2010/11/29)
The invention relates to methods of preparation for bis-amide complexing agents, as well as paramagnetic metal ion complexes that include such agents. To prepare these complexing agents, a reaction mixture is formed that includes a bis-anhydride, a nitrogen-containing compound, and an aqueous solvent system. The nitrogen-containing compound reacts with the bis-anhydride in the reaction mixture to form the bis-amide complexing agent. The molar ratio of water to the nitrogen containing compound in the reaction mixture is greater than 3:1, respectively. In addition, the molar ratio of the nitrogen-containing compound to the bis-anhydride in the reaction mixture is no greater than 2.5:1, respectively. In some embodiments, a base other than the nitrogen-containing compound may be included in the reaction mixture (e.g., to buffer the reaction mixture). In some embodiments, the bis-amide complexing agent may be contacted with a paramagnetic metal ion salt to form a paramagnetic metal ion complex of the invention.
